Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05270044
Title Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Pierre Fabre Medicament
Indications

skin melanoma

Therapies

Binimetinib + Encorafenib

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL | AUT

Additional content available in CKB BOOST